Europe Irritable Bowel Syndrome (IBS) Diagnostics Market Outlook and Insights by 2028

The Europe irritable bowel syndrome (IBS) diagnostics market is expected to reach US$ 1,191.44 million in 2028 from US$ 776.26 million in 2020; it is estimated to grow with a CAGR of 5.6% from 2021 to 2028.

The growth of the market is determined due to some of the key driving factors, such as increasing prevalence of irritable bowel syndrome and associated conditions and advancements in diagnostics of syndrome. On the other hand, challenges in diagnosis of IBS are likely to restraint the growth of market during the forecast years.

Irritable bowel syndrome is a chronic gastrointestinal condition that is caused due to disturbances in bowel habits and abdominal pain. People across the world are witnessing considerable incidence of irritable bowel syndrome. Certain factors such as food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are among the risk factors that cause irritable bowel syndrome. According to IBS Global Impact Report, in 2016, an estimated mean prevalence of Irritable Bowel Syndrome ranged to 1.1 % in France. Such staggering prevalence of irritable bowel syndrome is likely to boost the irritable bowel syndrome (IBS) diagnostics market during the forecast period. To cope up against irritable bowel syndrome, the companies involved in the drug development for irritable bowel syndrome are taking constructive steps to create awareness programs with an aim to spread awareness amongst the population. Such initiatives are anticipated to drive the growth of the irritable bowel syndrome (IBS) diagnostics market. Also, increasing number of FDA approvals and diagnostics development activities are likely to accelerate the growth of the irritable bowel syndrome (IBS) diagnostics market during the forecast period.

With the spread of the COVID-19 pandemic, it was discovered that a significant number of people around the world were suffering from Irritable Bowel Syndrome (IBS), as COVID-19 pandemic has affected the psychological health of people, resulting in a higher level of stress. Stress can exaggerate the symptoms of irritable bowel syndrome (IBS). Thus, the impact of COVID-19 is so far considered positive on the market. Therefore, the growing demand for Irritable Bowel Syndrome (IBS) Diagnostics in Europe is likely to boost the growth of the Irritable Bowel Syndrome (IBS) Diagnostics market.

 

EUROPE IRRITABLE BOWEL SYNDROME (IBS) DIAGNOSTICS MARKET SEGMENTATION

By Diagnosis

• Laboratory Tests
  • Lactose Intolerance Tests
  • Breath Test for Bacterial Overgrowth
  • Stool Tests
  • Stool Tests
• Imaging Tests
  • CT Scan or X-ray
  • Upper Endoscopy
  • Upper Endoscopy

By Indication

• Pain and Cramping
• Diarrhea
• Constipation
• Alternating Constipation and Diarrhea

By Country

• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe

Company Profiles

• Commonwealth Diagnostics International
• Genova Diagnostics
• Inova Diagnostics, Inc
• Biohit Oyj
• Aerodiagnostics, LLC.
• Sysmex Corporation (Sysmex Europe GmbH)
• BÜHLMANN Laboratories AG

Europe Irritable Bowel Syndrome (IBS) Diagnostics Report Scope